Zalicus Inc. ZLCS, a biopharmaceutical company that
discovers and develops novel treatments for patients suffering from pain,
today announced that it has been granted a patent by the U.S. Patent and
Trademark office (USPTO) covering its product candidate Z944. United States
patent number 8,377,968 entitled “N-Piperidinyl Acetamide Derivatives as
Calcium Channel Blockers” provides broad coverage for Z944 including
compositions of matter and certain therapeutic methods of use through April
2029. Z944 is a novel, oral, T-type calcium channel blocker which has
demonstrated efficacy in a number of preclinical inflammatory pain models and
other disease models. Z944 completed Phase 1 single and multiple ascending
dose clinical studies in late 2012 and the Company plans to continue further
clinical development with Z944 during 2013.
“This key patent provides the foundation of a solid and enforceable
intellectual property estate for Z944, with issued claims through April 2029,”
commented Mark H.N. Corrigan, MD, President and CEO of Zalicus. “Based on our
preclinical and early-stage clinical work, we are excited to further explore
the potential of Z944 as a novel, oral, non-opioid pain treatment.”
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in